Li et al. demonstrated that blocking CXCR4 signaling with AMD3100 significantly attenuated microglial activation and prevented dopaminergic neurodegeneration in MPTP-induced PD mouse models [32]. This evidence concerns the gene CXCR4 and Parkinson disease.